Chen Yaqin, Wu Gang, Zhang Hongmin, Xu Hua, Li Hong, Chen Ling, Yang Yixuan, Hu Peng, Zhang Dazhi, Ren Hong, Hu Huaidong
Department of Infectious Diseases, Institute for Viral Hepatitis, Key Laboratory of Molecular Biology for Infectious Diseases, The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China.
Department of Infectious Diseases, The Affiliated Hospital of Luzhou Medical College, Luzhou 646000, China.
Gastroenterol Res Pract. 2015;2015:206302. doi: 10.1155/2015/206302. Epub 2015 Jun 16.
Background. Graft reinfection with hepatitis C (HCV) after liver transplantation is a significant problem in transplant hepatology. This meta-analysis was performed to compare the effectiveness and risk of adverse events of interferon-based therapy with no treatment after liver transplantation. Methods. We searched electronic databases up to July 31, 2013, to obtain relevant research reports that satisfied the inclusion criteria. Meta-analyses were done on randomized controlled trials (RCTs) and nonrandomized trials. Results. A meta-analysis was performed on 2 RCTs and 2 cohort studies comprising a total of 326 patients (171 of whom accepted interferon-based antiviral therapy). The treatment group was found to have higher virological response (VR) rates than controls at 12, 24, 48, and 72 weeks. Patients in the antiviral group had higher sustained virological response (SVR) rates and lower mean alanine aminotransferase levels relative to controls at 48 weeks, but more total serious adverse events (AEs) than controls. Conclusions. Interferon-based treatment has some efficacy in the treatment of HCV graft reinfection following liver transplantation.
背景。肝移植后丙型肝炎病毒（HCV）移植物再感染是移植肝病学中的一个重要问题。本荟萃分析旨在比较肝移植后基于干扰素的治疗与不治疗的有效性及不良事件风险。方法。我们检索了截至2013年7月31日的电子数据库，以获取符合纳入标准的相关研究报告。对随机对照试验（RCT）和非随机试验进行荟萃分析。结果。对2项RCT和2项队列研究进行了荟萃分析，共纳入326例患者（其中171例接受基于干扰素的抗病毒治疗）。发现治疗组在12周、24周、48周和72周时的病毒学应答（VR）率高于对照组。抗病毒组患者在48周时的持续病毒学应答（SVR）率更高，平均丙氨酸转氨酶水平低于对照组，但总的严重不良事件（AE）比对照组更多。结论。基于干扰素的治疗在肝移植后HCV移植物再感染的治疗中具有一定疗效。
